Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Cannapharmarx Q3 2026 Results: Turns Profitable, Net Income $645K

CannaPharmaRx, Inc. reported a net loss of $1,645,647 for the nine months ended September 30, 2026, though it achieved a net income of $645,416 in the third quarter primarily due to non-cash gains from fair value adjustments. The company continues to operate with a significant shareholders' deficit of over $30 million and relies heavily on related party loans to fund its operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.10.7
Gross profit-0.3-0.4
Profit before tax0.6-1.5
Net income0.6-1.5
EPS (diluted, $ a share)$-0.00$-0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-79.0%
Gross margin-201.7%
Operating margin-387.0%
Source

10-Q filed with the SEC, CPMD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Cannapharmarx, Inc.: key numbers

Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.